Pfizer (NYSE:PFE - Get Free Report) will announce its earnings results before the market opens on Tuesday, July 30th. Analysts expect the company to announce earnings of $0.45 per share for the quarter. Pfizer has set its FY 2024 guidance at 2.150-2.350 EPS and its FY24 guidance at $2.15-2.35 EPS.Investors that wish to register for the company's conference call can do so using this link.
Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same quarter in the prior year, the firm earned $1.23 earnings per share. The company's revenue for the quarter was down 19.5% compared to the same quarter last year. On average, analysts expect Pfizer to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Pfizer Price Performance
Shares of Pfizer stock traded down $0.11 during trading hours on Tuesday, reaching $29.49. 25,495,628 shares of the company's stock were exchanged, compared to its average volume of 39,783,254. Pfizer has a 1 year low of $25.20 and a 1 year high of $37.80. The company has a market capitalization of $167.11 billion, a P/E ratio of -491.42, a price-to-earnings-growth ratio of 1.17 and a beta of 0.69. The business has a fifty day moving average of $28.45 and a two-hundred day moving average of $27.73. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.
Pfizer Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.70%. Pfizer's payout ratio is -2,799.53%.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on the stock. Barclays upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 10th. BMO Capital Markets reissued an "outperform" rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, July 10th. Finally, Morgan Stanley raised their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an "equal weight" rating in a research note on Thursday, May 2nd. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of "Hold" and a consensus price target of $34.50.
Check Out Our Latest Stock Analysis on PFE
Pfizer Company Profile
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
![Earnings History for Pfizer (NYSE:PFE)](https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NYSE&Symbol=PFE)
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.